ILMN Illumina Inc. Loading...

From DGX earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Oct 21 ◎
Jim Davis Chairman, CEO and President, Quest Diagnostics Incorporated DGX Q3 FY25 call
Quest's Alzheimer's blood test (AD-Detect) revenue more than doubled in Q3 following new clinical guidelines, signaling rapid market adoption and potential pressure on amyloid PET and CSF testing. — Blood-based biomarkers are displacing more expensive imaging and CSF tests, which could reduce volumes for PET tracer suppliers and CSF assay platforms.
ILMN
MED

About ILMN Analyst Coverage

Buzzberg tracks ILMN (Illumina Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Jim Davis.